Disc Medicine, Inc. · NASDAQ:IRON
Disc Medicine — Merger or Acquisition (January 2023)
13 slides from Disc Medicine's merger presentation, Jan 23, 2023
Slide 1: Novel Anti-TMPRSS6 Monoclonal Antibody Portfolio Exclusive In-Licensing Agreement with Mabwell Therapeutics
Novel Anti-TMPRSS6 Monoclonal Antibody Portfolio Exclusive In-Licensing Agreement with Mabwell Therapeutics January 20, 2023 Confidential Exhibit 99.2
Slide 2: Disclaimer and FLS
Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: future product development plans and projected timelines for the initiation a
Slide 3: Disc is Building a Leading Company Dedicated to Treating Hematologic Diseases
Disc is Building a Leading Company Dedicated to Treating Hematologic Diseases Fundamental & Validated Pathways Multiple Clinical Programs with Broad Potential Multiple Near-Term Catalysts Focus on Hematologic Disorders Immense medical need across a wide spectrum of disorders Predictive, objective en
Slide 4: Disc Targets Fundamental Pathways that Impact the Biology of Red Blood Cells
Disc Targets Fundamental Pathways that Impact the Biology of Red Blood Cells Erythropoietic Porphyrias CKD Anemia Sickle Cell Disease Myelodysplastic Syndromes Iron and heme formation play a central role in erythropoiesis Polycythemia Vera Critical points of intervention across multiple hematologic
Slide 5: Disc's Portfolio Addresses Broad Spectrum of Hematologic Disorders
Hepcidin Suppression Increase Iron Hepcidin Induction Reduce Iron Heme Synthesis Modulation Bitopertin (GlyT1 Inhibition) EPP, DBA, other rare blood disorders Phase 2 studies in EPP Phase 2 in DBA – init. 1H’23 DISC-0974 (Anti-HJV mAb) Anemia of MF, CKD, and other chronic diseases Phase 1b/2 MF Anem
Slide 6: Disc's Hematology-Focused Pipeline
Disc’s Hematology-Focused Pipeline Multiple programs in development with pipeline-in-a-product potential Preclinical Phase 1 Bitopertin† GlyT1 Inhibitor Oral, once-daily Phase 2 Near-Term Milestones DISC-0974‡ Anti-HJV monoclonal antibody Subcutaneous, once-monthly DISC-0998‡ Anti-HJV monoclonal ant
Slide 7: Disc is an expert in the role of iron homeostasis in the treatment of hematologic disorders
Disc is an expert in the role of iron homeostasis in the treatment hematologic disorders Aligns with Disc’s overall strategy of addressing hematologic diseases with high unmet need by targeting fundamental pathways in red blood cell biology Expanding Disc’s Portfolio in Benign Hematology In-licensin
Slide 8: Anti-TMPRSS6 mAb Induces Hepcidin
Promotes Iron Restriction Decreases GI Absorption Limits Iron Availability Increases Hepcidin Enables Endogenous Production of Hepcidin Erythrocytosis (PV) Ineffective Erythropoiesis Iron Overload Modulates RBC Production Anti-TMPRSS6 mAb Induces Hepcidin Designed to limit iron levels with potential
Slide 9: Targeting TMPRSS6 to Increase Hepcidin
Genetic validation in patients with IRIDA (Iron-Refractory Iron Deficiency Anemia) LOF TMPRSS6 mutation increases hepcidin and reduces iron availability Functionally specific to hepcidin / iron Tissue specific expression primarily in the liver Targeting TMPRSS6 to Increase Hepcidin Potent, specific
Slide 10: MWTX-003 Effects in Non-Human Primates
Potent PD effects observed across multiple preclinical studies consistent with TMPRSS6 inhibition Hepcidin: 3-4 fold induction Serum iron: ~ 60-70% suppression MWTX-003 demonstrated excellent safety profile in non-clinical GLP safety studies MWTX-003 Effects in Non-Human Primates Results in deep and
Slide 11: Effects in HbbTh3/+ Model of Beta-Thalassemia
Effects in HbbTh3/+ Model of Beta-Thalassemia Significant effects on hallmarks of disease including iron overload, ineffective erythropoiesis and splenomegaly HbbTh3/+ mice were treated with the lead anti-TMPRSS6 antibody at 10 mg/kg IP for 4 weeks ↓ Serum and Liver Iron 60-65% Reduction ↑ Hepcidin
Slide 12: MWTX-003 Development Plans
MTWX-003 Development Plans Establish phase 1 proof-of-mechanism and advance program into POC studies with focus on Polycythemia Vera Phase 1 SAD / MAD in HV Plan to Initiate 2H’23 Phase 1b / 2a Proof-of-Concept Study in Polycythemia Vera Additional POC Studies in a Range of Indications Demonstrate p
Slide 13: Novel Anti-TMPRSS6 Monoclonal Antibody Portfolio Exclusive In-Licensing Agreement with Mabwell Therapeutics
Novel Anti-TMPRSS6 Monoclonal Antibody Portfolio Exclusive In-Licensing Agreement with Mabwell Therapeutics January 20, 2023 Confidential